Login
$KPTI
$0.02 -$0.00 (7.47%) After hours

$KPTI 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

03 Nov 2026 8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +4 more

Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

02 Nov 2026 8-K: Regulation FD Disclosure

– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –

22 Oct 2026 8-K: Other Events

As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture...

14 Oct 2026 8-K: Other Events

As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,...

18 Sep 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ...

11 Sep 2026 8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more

This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi...

31 Aug 2026 8-K: Other Events

On August 31, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking Accelerated Approval for XPOVIO® (seli...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

31 Jul 2026 8-K: Other Events

On July 30, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type adv...

17 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 May 2026 8-K: Results of Operations and Financial Condition

– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 –

27 Mar 2026 8-K: Other Events

On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares of its ...

24 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 24, 2026, by and among Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), and the purchaser listed on Exhibit A attached to this Agreement (the...

03 Mar 2026 8-K: Entry into a Material Definitive Agreement; Other Events

SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT, dated as of February 27, 2026 (this “Amendment”), made by and among Karyopharm Therapeutics Inc., a Delaware corporation (“Company”) as borrower, the Lenders party hereto from time to ti...

19 Feb 2026 8-K: Submission of Matters to a Vote of Security Holders

On February 18, 2026, Karyopharm Therapeutics Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The following is a summary of the matters voted on at the Special Meeting.

12 Feb 2026 8-K: Results of Operations and Financial Condition

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

12 Jan 2026 8-K: Results of Operations and Financial Condition; Other Events

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

03 Nov 2025 8-K: Results of Operations and Financial Condition

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support